Wade Thompson1,2, Cody Black3,4, Vivian Welch3,4,5, Barbara Farrell4,6, Lise M Bjerre3,4,6, Peter Tugwell3,4,5,7. 1. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada. wthomp01@gmail.com. 2. Bruyère Research Institute, 43 Bruyère Street, Ottawa, ON, K1N 5C8, Canada. wthomp01@gmail.com. 3. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada. 4. Bruyère Research Institute, 43 Bruyère Street, Ottawa, ON, K1N 5C8, Canada. 5. Centre for Global Health, Ottawa, ON, Canada. 6. Department of Family Medicine, University of Ottawa, Ottawa, ON, Canada. 7. Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Abstract
BACKGROUND: Proton pump inhibitors (PPIs) treat various upper gastrointestinal (GI) diseases. Around 50% of patients may remain on PPIs long-term without ongoing need. Eligible patients should be offered the choice of continuing their PPI or trying to reduce/stop their PPI (deprescribing), a choice dependent on values and preferences. OBJECTIVES: Our objective was to systematically scope the available evidence on patient values and preferences surrounding continued PPI treatment and/or the decision to try a reduction in their PPI. We searched the MEDLINE, Embase, and Cochrane Library databases and the grey literature as of 9 August 2016 for studies of any design examining patient values and preferences toward PPI treatment and/or deprescribing. We included patients aged ≥18 years taking PPIs for upper GI diseases. RESULTS: We located 12 eligible studies (seven surveys, four qualitative studies, one randomized controlled trial). One study only examined values and preferences towards reducing PPI use, five studies looked only at PPI treatment (initiation/continuation), four studies assessed both PPI treatment and reduction, and two studies evaluated PPI treatment and switching (to alternative PPIs). Patients value symptom control highly and worry about symptoms returning if the PPI is reduced. They are encouraged to consider reducing their PPI if a clinician provides advice and education. All five studies that examined reducing PPI use suggest patients should understand the rationale for considering continuation versus deprescribing of PPIs and should know what to expect from deprescribing. Patients are encouraged by knowing they can return to their previous dose if necessary. Our results were limited by the small sizes of studies and the heterogeneous populations. CONCLUSION: Patients are willing to discuss the option of continuing PPI use or trying to reduce their PPI; however, a range of attitudes exist. The results suggest that reducing a PPI is a preference-sensitive decision. Therefore, patient attitudes should be elicited and incorporated into shared decision making surrounding the decision to continue or try deprescribing a PPI, and structured tools will be helpful to encourage this.
BACKGROUND:Proton pump inhibitors (PPIs) treat various upper gastrointestinal (GI) diseases. Around 50% of patients may remain on PPIs long-term without ongoing need. Eligible patients should be offered the choice of continuing their PPI or trying to reduce/stop their PPI (deprescribing), a choice dependent on values and preferences. OBJECTIVES: Our objective was to systematically scope the available evidence on patient values and preferences surrounding continued PPI treatment and/or the decision to try a reduction in their PPI. We searched the MEDLINE, Embase, and Cochrane Library databases and the grey literature as of 9 August 2016 for studies of any design examining patient values and preferences toward PPI treatment and/or deprescribing. We included patients aged ≥18 years taking PPIs for upper GI diseases. RESULTS: We located 12 eligible studies (seven surveys, four qualitative studies, one randomized controlled trial). One study only examined values and preferences towards reducing PPI use, five studies looked only at PPI treatment (initiation/continuation), four studies assessed both PPI treatment and reduction, and two studies evaluated PPI treatment and switching (to alternative PPIs). Patients value symptom control highly and worry about symptoms returning if the PPI is reduced. They are encouraged to consider reducing their PPI if a clinician provides advice and education. All five studies that examined reducing PPI use suggest patients should understand the rationale for considering continuation versus deprescribing of PPIs and should know what to expect from deprescribing. Patients are encouraged by knowing they can return to their previous dose if necessary. Our results were limited by the small sizes of studies and the heterogeneous populations. CONCLUSION:Patients are willing to discuss the option of continuing PPI use or trying to reduce their PPI; however, a range of attitudes exist. The results suggest that reducing a PPI is a preference-sensitive decision. Therefore, patient attitudes should be elicited and incorporated into shared decision making surrounding the decision to continue or try deprescribing a PPI, and structured tools will be helpful to encourage this.
Authors: Khean Lee Goh; Myung Gyu Choi; William Ping I Hsu; Hoon Jai Chun; Varocha Mahachai; Udom Kachintorn; Somchai Leelakusolvong; Nayoung Kim; Abdul Aziz Rani; Benjamin Cy Wong; Justin Wu; Cheng Tang Chiu; Romeo Chu; Vikram Shetty; Joseph C Bocobo; Melchor M Chan; Jaw Town Lin Journal: J Gastroenterol Hepatol Date: 2014-12 Impact factor: 4.029
Authors: Wade Thompson; Barbara Farrell; Vivian Welch; Peter Tugwell; Cynthia Way; Lisa Richardson; Lise M Bjerre Journal: Can Pharm J (Ott) Date: 2018-12-17
Authors: Claudia Bruno; Sallie-Anne Pearson; Benjamin Daniels; Nicholas A Buckley; Andrea Schaffer; Helga Zoega Journal: BMJ Qual Saf Date: 2019-10-22 Impact factor: 7.035
Authors: Devada Singh-Franco; David R Mastropietro; Miriam Metzner; Michael D Dressler; Amneh Fares; Melinda Johnson; Daisy De La Rosa; William R Wolowich Journal: PLoS One Date: 2020-12-03 Impact factor: 3.240